Management ChangeMay 15, 2026, 04:07 PM
Rani Therapeutics CFO Sanford to Depart; Q1 Net Loss $8.0M
AI Summary
Rani Therapeutics announced that CFO Svai Sanford will transition from his role, with a search for a successor initiated. The company also reported Q1 2026 financial results, showing a reduced net loss of $8.0 million and increased contract revenue of $1.7 million. Additionally, Rani strengthened its leadership team with the promotion of Alireza Javadi to CTO and the appointments of Jesper Høiland as Head of Strategy and Dr. Sara Kenkare-Mitra as Strategic Advisor, while continuing to advance its Phase 1 study of RT-114 for obesity.
Key Highlights
- CFO Svai Sanford will transition from his role, with a search for a successor underway.
- Alireza Javadi, Ph.D. was promoted to Chief Technical Officer in January 2026.
- Jesper Høiland was appointed Head of Strategy in March 2026.
- Dr. Sara Kenkare-Mitra was appointed Strategic Advisor in April 2026.
- Continued advancement of the Phase 1 study of RT-114 for obesity.
- Q1 2026 contract revenue increased to $1.7 million from $0.2 million YoY.
- Q1 2026 net loss decreased to $8.0 million from $12.7 million YoY.
- Cash, cash equivalents, and marketable securities totaled $43.4 million as of March 31, 2026.
Price Impact
More from RANI